FDA Limits Use of AstraZeneca COVID Antibody Treatment

Published on January 26, 2023

The FDA has put a pause on the use of AstraZeneca’s COVID-19 antibody treatment, Evusheld. It’s like stopping the production of a new type of amazing playground slide because there are concerns that it might not be safe for kids to use. The therapy, which was thought to provide protection against the current dominant strains of COVID-19, is now on hold until further investigations can confirm its safety and efficacy. While this temporary halt may be disappointing, it also highlights the FDA’s commitment to ensuring the highest safety standards for the public. This move serves as a reminder that even with promising advancements in COVID-19 treatments, thorough testing and regulatory oversight are indispensable. To learn more about the ongoing research and developments in this field, don’t forget to explore the underlying article!

AstraZeneca’s COVID-19 antibody cocktail Evusheld is not currently authorized for use in the United States until further notice, the U.S. Food and Drug Administration said on Thursday. The therapy is unlikely to provide protection against currently dominant COVID-19…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>